VivoSeq
Other

Contraception

83

Pipeline Programs↗

9

Active Trials↗

24

Companies Involved↗

Contraception is a moderately active landscape with 83 programs across 24 companies. The most active players are Auxilium, Watson Pharmaceuticals, Medicines360. 29 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

92/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Auxilium

1 program

Phase 1W

Watson Pharmaceuticals

1 program

Phase 3M

Medicines360

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3L

Laboratoire français de Fractionnement et de Biotechnologies

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical27

Ulipristal Acetate

AbbVie

Naproxen Sodium

Bayer

Dienogest

Bayer

Ketorolac

Javelin Pharmaceuticals

Mifepristone Combined Misoprostol

Taizhou Hospital

Phase 19

Testosterone

Auxilium

Dimethandrolone-Undecanoate

Premier Research

Acyline

University of Washington

Depot-Medroxyprogestereone Acetate

University of Southern California

Contraceptive

GSK

Phase 23

Veracept

Sebela Women's Health Inc.

Drospirenone-Only Pill

University of Colorado, Denver

Nestorone /testosterone

Kimberly Myer

Phase 315

Medroxyprogesterone Acetate

Eli Lilly

Estradiol Valerate

Bayer

Piroxicam

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Yasmin

Bayer

Norethindrone Acetate

Watson Pharmaceuticals

Approved29

Misoprostol

Pfizer

Cilostazol

Otsuka

Estradiol

Novo Nordisk

Levonorgestrel

Italian Network for Tumor Biotherapy Foundation

Relugolix

Sumitomo Pharma America, Inc.

Analysis

Modality Breakdown

99%

Small molecule

102 of 103 classified programs — the dominant modality here.

1%ALL OTHERSProtein / enzyme1<1%

Small molecule leads; the ring shows all 103 classified programs, each share of the total. Modality classified for 100% of 103 pipeline programs.

Analysis

Trial Status

88

clinical trials

Completed69 · 78%
Terminated5 · 6%
Recruiting4 · 5%
Unknown status4 · 5%
Not yet recruiting3 · 3%
Active, not recruiting2 · 2%
Other1 · 1%

Clinical Trials

Trial Activity

88 trials

Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
Recruiting·—·Phase 4·NCT06162611·790 enrolled
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
Recruiting·UUniversity of Utah·Phase 4·NCT05444582·1,404 enrolled
Etonogestrel Implant as Emergency Contraception
Recruiting·UUniversity of Colorado, Denver·Phase 4·NCT05237141·12 enrolled
A Prospective Observational Study on the Contraceptive Effectiveness of the Natural Cycles Application (The VENUS Study)
Recruiting·—·N/A·NCT07566793·2,000 enrolled
Quick Start of Highly Effective Contraception
Active, not recruiting·UUniversity of Utah·N/A·NCT02076217·1,030 enrolled
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
Active, not recruiting·PPremier Research·Phase 1·NCT04143659·136 enrolled
Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception
Not yet recruiting·TThe University of Hong Kong·Phase 3·NCT06727734·980 enrolled
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
Not yet recruiting·PPremier Research·Phase 2·NCT07222228·165 enrolled
Prospective Elavulation of the Safety of a Novel Copper Vaginal Contraceptive Ring (CVR)
Not yet recruiting·EElle, MD Biotechnologies Inc.·Preclinical·NCT07666997·8 enrolled
Medical Abortion for Emergency Contraception Failure
Completed·TTaizhou Hospital·N/A·NCT00677755·394 enrolled
Same-day Long-acting Reversible Contraception for Medication Abortion
Completed·—·N/A·NCT01356927·40 enrolled
Human Ovarian Follicular Dynamics and Emergency Contraception
Completed·UUniversity of Saskatchewan·Phase 4·NCT00204451·40 enrolled
Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception
Completed·—·N/A·NCT01240811·42 enrolled
Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction
Completed·Bayer logoBayer·N/A·NCT01200186·3,258 enrolled
Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception
Completed·MMahidol University·Phase 4·NCT03077555·69 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)